BioGaia Osfortis (L. reuteri 6475)

Rating breakdown

Evidence for ingredient 7.0/10

Strain-specific RCT (n=90, 12 months, Journal of Internal Medicine) showed significant reduction in bone loss. Unusually strong evidence for a probiotic.

Value for money 5.0/10

€1.00 per day is premium pricing, but standard for a patented, strain-specific probiotic.

Product quality 9.0/10

BioGaia is the original developer of the strain — the exact strain used in the RCT, with no generic alternative.

Label honesty 10.0/10

Strain designation ATCC PTA 6475 precisely stated, CFU amount declared, BioGaia holds the patent.

Third-party testing 8.0/10

BioGaia is a publicly traded Swedish biotech company operating to pharmaceutical standards.

Product Description

BioGaia Osfortis contains 10 billion CFU of the patented strain L. reuteri ATCC PTA 6475 per capsule. BioGaia developed this strain and holds the patents — there are no generic alternatives using the same strain. The product is specifically designed for bone health in postmenopausal women.

What We Like

Exact strain from the Nilsson RCT — no interpretation needed
BioGaia as original manufacturer guarantees strain identity
10^10 CFU — exact dosage used in the study
Pharmaceutical quality standards from a publicly listed biotech company
Well-researched: 4+ published studies on this specific strain

What We’re Missing

€1.00/day is the highest daily cost in our probiotic segment
Only 30 capsules = 1 month supply
Evidence limited to older women with low BMD — transferability to other groups unclear
Availability varies across EU countries

Usage Recommendation

1 capsule daily, independent of meals. Take for at least 12 months (study duration). Bone health is a long-term topic — short-term use is not meaningful.